论文部分内容阅读
目的研究强肝抗纤汤对大鼠肝纤维化的防治作用,为强肝抗纤汤的临床应用提供实验依据。方法将62只SPF级大鼠随机分为空白组,模型组,秋水仙碱组,中药低、高剂量组5组。采用复合因素法复制肝纤维化模型,造模前1 d,各组分别灌胃生理盐水或相应药物。造模及灌胃给药共进行6周,6周后对各组大鼠血清丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)含量进行检测,并进行大鼠肝脏病理形态学观察。结果与空白组比较,模型组大鼠ALT,AST含量显著升高,差异有高度统计意义(P<0.01);与模型组比较,各治疗组大鼠ALT,AST含量显著降低,差异有统计意义(P<0.05或P<0.01);与秋水仙碱组比较,强肝抗纤汤高、低剂量组ALT,AST含量降低更为显著,差异有高度统计意义(P<0.01)。结论强肝抗纤汤可有效预防实验大鼠肝纤维化形成,降低肝纤维化大鼠肝组织损伤程度,有效降低肝纤维化模型大鼠血清ALT,AST含量。
Objective To study the preventive and therapeutic effects of Qianggan Kangxian Tang on hepatic fibrosis in rats and to provide experimental evidence for its clinical application. Methods Sixty two SPF rats were randomly divided into five groups: blank control group, model group, colchicine group and low and high dose Chinese medicine groups. Hepatic fibrosis model was replicated by composite factor method. One day before model establishment, each group was given normal saline or corresponding drugs. After six weeks and six weeks, the levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in rats in each group were measured, and the rat liver Pathological observation. Results Compared with the blank group, the contents of ALT and AST in the model group were significantly increased (P <0.01). Compared with the model group, the contents of ALT and AST in the treated group were significantly decreased, with statistical significance (P <0.05 or P <0.01). Compared with the colchicine group, the levels of ALT and AST in the Qianggan Kangxian Tang high and low dose groups were significantly lower (P <0.01). CONCLUSION Qianggan Kangxian Tang can effectively prevent the formation of hepatic fibrosis, reduce the degree of hepatic tissue injury in rats with hepatic fibrosis and effectively reduce the levels of serum ALT and AST in rats with hepatic fibrosis.